Related Experiment Videos
Treatment of constipation with chenodeoxycholic acid
The Journal of International Medical Research
|January 1, 1983
Summary
Chenodeoxycholic acid (CDCA) significantly improved chronic constipation by increasing stool frequency and reducing consistency in a 4-week study. Further research is needed to optimize CDCA dosage for individual patient needs.
Area of Science:
- Gastroenterology
- Pharmacology
Background:
- Chronic constipation affects a significant portion of the population.
- Current management strategies may have limitations or side effects.
- Chenodeoxycholic acid (CDCA) is known for its cathartic properties.
Purpose of the Study:
- To evaluate the efficacy of chenodeoxycholic acid (CDCA) in managing chronic constipation.
- To assess the impact of CDCA on stool frequency and consistency.
Main Methods:
- A randomized, placebo-controlled trial involving 20 patients with chronic constipation and gallstones.
- Patients received either CDCA (750 mg/day) or a placebo for 4 weeks.
- Bowel habits, including stool frequency and consistency, were monitored.
Main Results:
- CDCA administration led to a significant increase in stool frequency.
- CDCA treatment resulted in a significant decrease in stool consistency.
- Placebo treatment showed no significant improvement in bowel habits.
Conclusions:
- Chenodeoxycholic acid (CDCA) demonstrates potential as a therapeutic agent for chronic constipation.
- Individualized dosing may be necessary to mitigate side effects like diarrhea and maximize efficacy.
- Further clinical studies are warranted to establish optimal CDCA dosage regimens.